Before last month, David W. Smith was a midlevel executive at the sprawling health services company Optum. He’d never met the company’s CEO, according to a sworn affidavit, or cracked into a senior leadership team that includes about 200 people. He was basically a strategy consultant.

But on Dec. 11, he became an existential threat. He took a job working for a nascent competitor, the health venture formed by Amazon, Berkshire Hathaway, and JPMorgan Chase & Co and helmed by Dr. Atul Gawande.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy